← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
anti-GPC3 CAR-T (anti-GPC3 CAR-T)
CARsgen Therapeutics Co., Ltd.·Advanced Hepatocellular Carcinoma
11 trials
Overview
Program
anti-GPC3 CAR-T
Overview
Company
CARsgen Therapeutics Co., Ltd.
Overview
Modality
CGT
Overview
Target
Advanced Hepatocellular Carcinoma
Overview
Indication
Advanced Hepatocellular Carcinoma
Overview
Phase
PHASE_1
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Enhanced Functionality of Anti-GPC3 CAR-T Cells Against Hepatocellular Carcinoma Through Locoregional Administration.. The prognosis for patients with hepatocellular carcinoma (HCC) remains suboptimal, despite the rapid advancement of anti-cancer immunotherapy. Chimeric antigen receptor (CAR) T cell therapy targeting glypican-3 (GPC3) has been developed for HCC; however, clinical trials have demon…
Toxicology
CRS
Grade 2
Clinical
Safety signal
Enhanced Functionality of Anti-GPC3 CAR-T Cells Against Hepatocellular Carcinoma Through Locoregional Administration.. The prognosis for patients with hepatocellular carcinoma (HCC) remains suboptimal, despite the rapid advancement of anti-cancer immunotherapy. Chimeric antigen receptor (CAR) T cell therapy targeting glypican-3 (GPC3) has been developed for HCC; however, clinical trials have demon…
Clinical
Program phase
PHASE_1